Imatib 100mg Capsule

Imatinib belongs to a class of medications known as tyrosine kinase inhibitors, specifically designed to target the BCR-ABL protein, an abnormal enzyme produced by a genetic mutation found in chronic myeloid leukemia (CML) and certain other blood cancers. By blocking this protein's activity, Imatinib helps stop the uncontrolled growth and division of cancer cells that rely on this specific pathway. It is commonly used as a first-line treatment for CML, helping many patients achieve long-term disease control and, in some cases, deep and lasting remission. Imatinib is also used to treat certain gastrointestinal stromal tumors (GISTs) and other rare cancers that share the same genetic characteristics this medication targets. As an oral targeted therapy, Imatinib represented an important advancement in cancer treatment, offering a more precise approach with a more convenient dosing schedule compared to traditional chemotherapy. The tablets are typically taken once daily with food, following a schedule established by a hematologist or oncologist based on the specific condition and patient response. Regular monitoring, including blood tests and periodic genetic testing, helps track treatment response and guide any necessary adjustments over time. Many patients with CML experience excellent, long-term disease control with consistent use of Imatinib as part of their treatment plan. As with all targeted cancer therapies, Imatinib tablets should be used strictly under the guidance of an experienced hematology or oncology healthcare provider.